This inventor holds 3 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 2009-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hamburg, DE (2009 - 2011)
- Carmel, IN (US) (2016)
Company Filing History:
Years Active: 2009-2016
Title: The Innovative Contributions of Bengt Krister Bokvist in Diabetes Research
Introduction: Bengt Krister Bokvist, based in Hamburg, Germany, is a notable inventor with a focus on developing compounds that can significantly influence the treatment of type 2 diabetes mellitus (T2D). With three patents to his name, his work emphasizes the synthesis of innovative therapeutic solutions.
Latest Patents: Among his latest patents are the "GIP and GLP-1 co-agonist compounds," which concern dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These groundbreaking compounds are aimed at treating type 2 diabetes mellitus effectively. Another significant patent is for "Selective VPAC2 receptor peptide agonists," which includes peptides that selectively activate the VPAC2 receptor. This invention plays a critical role in the treatment of diabetes, thereby showcasing Bokvist's commitment to addressing crucial health challenges.
Career Highlights: Bengt Krister Bokvist currently works at Eli Lilly and Company, where he continues to push the boundaries of diabetes research through his inventive prowess. His contributions to the field have opened new avenues for the treatment of one of the most prevalent metabolic disorders worldwide.
Collaborations: Throughout his career, Bokvist has collaborated with talented professionals in the industry, including Jorge Alsina-Fernandez and Lianshan Zhang. These partnerships undoubtedly enhance the impact of his innovations and provide a platform for collective advancements in diabetes treatment.
Conclusion: Bengt Krister Bokvist stands out as an influential inventor in the realm of diabetes research. His patents and collaborative efforts highlight the importance of innovation in developing effective treatments for complex health issues like type 2 diabetes mellitus. As he continues to contribute to this vital field, his work inspires hope for improved therapeutic options for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile